Safety, Tolerability and Pharmacodynamic Effect of Fazirsiran (TAK-999, ARO-AAT)
Trial details
- Registry ID
- NCT03945292
- Phase
- Phase 2
Drug identity checked against registry records
Also recorded as ARO-AAT Injection; TAK-999 Injection
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Safety, Tolerability and Pharmacodynamic Effect of Fazirsiran (TAK-999, ARO-AAT)NCT03945292 | Arrowhead Pharmaceuticals | Phase 2 | Completed | 2021-11-08Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |